Novo Nordisk vs. Dr. Reddy’s: Liraglutide Patent Dispute Dismissed After 135 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Dr. Reddy’s Laboratories, Ltd. |
| Case Number | 1:23-cv-22112 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Nov 2023 – Mar 2024 135 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Generic Liraglutide Solution Injection (18 mg/3 ml, 6 mg/ml) |
Case Overview
The Parties
⚖️ Plaintiff
Danish multinational pharmaceutical company and global leader in diabetes care, holding an extensive patent portfolio covering GLP-1 receptor agonist therapies.
🛡️ Defendant
Major Indian multinational generic pharmaceutical manufacturer with substantial ANDA filing activity across therapeutic categories.
Patents at Issue
This ANDA litigation involved two patents covering formulation or composition aspects of liraglutide injectable solution, essential to Novo Nordisk’s proprietary GLP-1 products. These patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect specific technical innovations rather than just active pharmaceutical ingredients.
- • U.S. Patent No. 8,114,833 — covering formulation or composition aspects of liraglutide injectable solution
- • U.S. Patent No. 9,265,893 — covering related therapeutic or formulation innovations for liraglutide delivery
Developing a generic equivalent?
Check if your generic drug formulation might infringe these or related patents before ANDA submission.
The Verdict & Legal Analysis
Outcome
The case was **dismissed without prejudice** pursuant to a joint stipulation agreed upon by both Novo Nordisk and DRL. No damages were awarded, no injunctive relief was formally issued, and no judicial determination on patent validity or infringement was made on the merits. Each party agreed to bear its own attorneys’ fees and costs — a standard feature of negotiated pharmaceutical patent settlements.
Critically, the dismissal without prejudice means **neither party is legally barred from future litigation** on these patents should circumstances change.
Key Legal Issues
From a Hatch-Waxman litigation standpoint, the preservation of DRL’s Paragraph IV certification is the most legally notable element of this dismissal. Under the Hatch-Waxman framework, a Paragraph IV certification asserts that listed patents are invalid, unenforceable, or not infringed by the ANDA product. By stipulating that DRL may **maintain** this certification, the parties have effectively acknowledged that the underlying patent challenge remains unresolved on the merits.
This structure is consistent with settlements that include a **licensed entry date** — where the generic manufacturer agrees to delay commercial launch until a negotiated date in exchange for a license, while nominal certification status is preserved for regulatory purposes. The specific terms of any such arrangement between Novo Nordisk and DRL were not disclosed in the public court record.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in generic drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation on pharmaceutical formulations.
- View all related patents in the GLP-1 space
- See key players in liraglutide generics
- Understand formulation claim scope
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic formulation.
- Input your generic drug description or technical features
- AI identifies potentially blocking formulation patents
- Get actionable FTO risk assessment report
High Risk Area
Liraglutide formulations (6 mg/ml concentration)
2 Patents in this case
Formulation & delivery innovations
Design-Around Options
Limited for biologics/formulations
✅ Key Takeaways
Early settlement in ANDA litigation can preserve commercial exclusivity without the cost and uncertainty of full trial.
Search related ANDA case law →Maintaining Paragraph IV certification in settlement is a sophisticated drafting technique with regulatory consequences for generic entry.
Explore ANDA litigation precedents →Frequently Asked Questions
U.S. Patent Nos. 8,114,833 and 9,265,893, both covering aspects of liraglutide recombinant solution injection formulated at 6 mg/ml concentration.
The parties reached a private resolution and jointly stipulated to dismissal. No court ruled on patent validity or infringement. Dismissal without prejudice preserves both parties’ future litigation rights.
DRL’s ANDA No. 214411 remains pending with Paragraph IV certification intact. Any confidential settlement terms — including authorized entry dates — will govern actual generic market entry timing, not the public court record.
Brand companies can protect themselves by building multi-layered patent portfolios, promptly filing infringement actions within 45 days of Paragraph IV notice, and strategically negotiating settlements that control generic market entry. Generic companies must conduct robust FTO and invalidity analysis before filing ANDAs to assess litigation risk.
Ready to Strengthen Your Pharma Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharmaceutical sector.
References
- United States District Court for the District of New Jersey — Case 1:23-cv-22112
- U.S. Patent and Trademark Office — Patent Center
- U.S. Food & Drug Administration — ANDA Database
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence for Pharmaceutical & Biotech
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.